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Migration of monocytes into the vessel wall contributes to
the onset and progression of atherosclerosis. Because
monocytes are a heterogeneous population, we determined
potential associations between monocyte subsets and
cardiovascular events in a prospective cohort of 94 dialysis
patients followed for 35 months. The incidence of
cardiovascular events and death measured by Kaplan–Meier
plots and flow cytometric analysis of monocyte subsets
showed that total leukocyte and monocyte numbers failed to
predict event-free survival. Among monocyte subsets, a high
CD14þ þCD16þ monocyte number was associated with
higher rates of cardiovascular events and death. In a
multivariate proportional hazards model adjusted for
classical cardiovascular risk factors, patients with
CD14þ þCD16þ monocyte numbers in the top quartile were
at higher risk of cardiovascular events and death compared
to patients in the lowest quartile. Our study suggests that the
number of CD14þ þCD16þ monocytes was independently
associated with cardiovascular events and death in a
high-risk population of dialysis patients.
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Dialysis patients have a 40–400 times higher risk of
cardiovascular disease (CVD) mortality than age-matched
individuals from the general population.1 Although tradi-
tional cardiovascular risk factors are common among dialysis
patients,2 they only account for a fraction of the excess risk
for CVD in these patients.3
Instead, non-traditional risk factors have been shown to
contribute to the burden of CVD in dialysis patients. Among
these, the immune system is one of the dominant factors
modulating atherogenesis in dialysis patients, as reviewed
recently.4 Earlier reports focused on the association between
soluble inflammatory markers, such as C-reactive protein
(CRP) and proinflammatory cytokines, and cardiovascular
events.5,6 However, the importance of these markers as
predictors of cardiovascular mortality in patients with
chronic renal disease has recently been questioned.7,8
The link between cellular immunity and CVD in dialysis
patients has received little attention in clinical studies,
although components of the cellular immune system may
be important and possibly even obligatory contributors to
atherogenesis.9,10
The recruitment of monocytes into the vessel wall is an
important step for the onset and progression of athero-
sclerosis. In atherosclerotic lesions, monocyte-derived cells
take up modified lipoproteins and produce secretory factors
that attract and activate smooth muscle cells, additional
monocytes, and other immune cells.11
Surprisingly, total leukocyte and neutrophil counts are
stronger predictors of cardiovascular events than monocyte
counts in the general population, even though no important
role of neutrophils in atherogenesis has been described so
far.12–14 Similarly, high total leukocyte, high neutrophil, and
low lymphocyte counts are associated with cardiovascular
events and mortality in dialysis patients,15–18 whereas the
impact of monocyte counts on cardiovascular events has not
been studied before.
In the last decade, monocyte heterogeneity has widely
been acknowledged.19–21 Recently, in vitro and animal studies
suggested a selective role of distinct monocyte subpopu-
lations in the development of atherosclerosis.22 In humans,
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both chronic kidney disease23 and coronary artery disease24
are associated with changes in differential monocyte counts.
This study tested the hypothesis that cell counts of distinct
monocyte subsets rather than total monocyte counts predict
cardiovascular events in dialysis patients.
RESULTS
The baseline characteristics of all 94 dialysis patients are
shown in Table 1.
A total of 50 patients had died (n¼ 37), had a cardio-
vascular event (n¼ 27), or both by the time of the last follow-
up. Eleven patients were censored after receiving a renal
allograft without a prior cardiovascular event. The mean
follow-up of the remaining 33 patients was 35±1 months.
As expected, patients who suffered an event were older, had
a higher baseline CRP, and a higher prevalence of CVD or
diabetes mellitus at baseline; in addition, they had a lower
baseline blood pressure (Table 1).
Compared to 27 age-matched controls (C) without
chronic kidney disease, dialysis patients (D) had increased
counts of CD14þ þCD16þ monocytes (D: 53±33 cellsml1,
C: 29±13 cellsml1, Po0.001) and CD14þCD16þ mono-
cytes (D: 130±76 cellsml1, C: 70±33 cellsml1, Po0.001),
whereas counts of CD14þ þCD16 monocytes were lower
than in controls (D: 439±219 cellsml1, C: 504±184 cellsml1,
P¼ 0.040; compare Figure 1 for a representative example).
Hemodialysis patients (HDs) had significantly higher counts of
CD14þ þCD16þ and CD14þCD16þ monocytes compared
to patients on peritoneal dialysis (PD) treatment, whereas the
difference in CD14þ þCD16 monocyte counts did not
reach statistical significance (CD14þ þCD16 cells: HD 455±
235 cellsml1, PD 376±126 cellsml1, P¼ 0.165; CD14þ þ
CD16þ cells: HD 57±34 cellsml1, PD 37±22 cellsml1, P¼
0.006; CD14þCD16þ cells: HD 140±79 cellsml1, PD 91±
50 cellsml1, P¼ 0.008). HD patients were significantly older
than PD patients, and the prevalence of diabetes mellitus was
significantly higher among HD patients. As a result, dialysis
modality did not remain a significant predictor of monocyte
subset counts after adjustment for classical cardiovascular risk
factors (data not shown).
Total and differential monocyte counts did not differ
between male and female patients, between diabetic and non-
diabetic patients, and between smokers and non-smokers
(data not shown). Patients with prevalent CVD at study entry
had higher counts of total and CD14þ þCD16þ monocytes
than patients without prevalent CVD (total monocytes:
697±324 vs 571±229 cells, P¼ 0.014; CD14þ þCD16þ
monocytes: 61±34 vs 47±31 cells, P¼ 0.016).
Among the 94 patients, there was a positive correlation
of total monocyte counts with age and a negative correlation
of total and CD14þ þCD16þ monocyte counts with high-
density lipoprotein cholesterol and with mean blood pressure
(Table 2). In addition, CD14þ þCD16þ monocytes were
negatively correlated with total cholesterol, and CD14þ
CD16þ monocytes were negatively correlated with high-
density lipoprotein cholesterol. There was no significant
Table 1 | Baseline characteristics of the study cohort
Overall (n=94) No event (n=44) Event (n=50) P-value
Age (years) 65.5±13.8 59.0±13.7 71.1±11.4 o0.001
Women (%) 37 (39%) 20 (45%) 17 (34%) 0.294
Vintage of renal replacement therapy (years) 3.7±4.5 4.3±4.2 3.2±4.8 0.101
Smokers (%) 12 (13%) 9 (20%) 3 (6%) 0.060
Mean blood pressure (mm Hg) 97.1±16.6 101.2±17.7 93.5±14.8 0.037
Prevalent cardiovascular disease (%) 38 (40%) 9 (20%) 29 (58%) o0.001
Prevalent coronary artery disease (%) 28 (30%) 6 (14%) 22 (44%) 0.002
Prevalent cerebrovascular disease (%) 8 (9%) 2 (5%) 6 (12%) 0.276
Prevalent peripheral artery disease (%) 11 (12%) 2 (5%) 9 (18%) 0.056
Diabetes mellitus (%) 38 (40%) 12 (27%) 26 (52%) 0.020
C-reactive protein (mg l1) 17.0±23.4 8.8±11.6 24.1±28.4 o0.001
Total cholesterol (mg per 100 ml) 170.5±48.6 172.2±42.7 169.0±53.7 0.527
HDL cholesterol (mg per 100 ml) 49.9±15.9 50.6±17.9 49.3±14.1 0.943
Body mass index (kg m2) 25.1±4.4 25.6±4.4 24.7±4.3 0.363
Plasma calcium (mmol l1) 2.3±0.2 2.3±0.2 2.3±0.2 0.416
Plasma phosphorus (mg per 100 ml) 6.2±1.6 6.1±1.6 6.2±1.6 0.961
Albumin (g l1) 38±4 40±3 37±3 o0.001
Leukocytes per ml 6900±2170 6795±2355 6992±2013 0.292
Monocytes per ml 622±277 591±325 650±227 0.030
Medicationa
ACE inhibitor (%) 9 (10%) 4 (9%) 5 (10%) 1.000
AT-1 antagonist (%) 22 (24%) 9 (20%) 13 (27%) 0.626
Calcium antagonist (%) 44 (47%) 19 (43%) 25 (51%) 0.534
Antiplatelet therapy (%) 38 (41%) 13 (30%) 25 (51%) 0.057
b-blocker (%) 44 (47%) 20 (46%) 24 (49%) 0.836
ACE, angiotensin-converting-enzyme; HDL, high-density lipoprotein.
aData on baseline medication are missing in one patient.
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correlation between total and differential monocyte counts
and CRP.
Figure 2 shows the survival without cardiovascular events
of the cohort per quartile of total and differential leukocyte
cell counts (unadjusted Kaplan–Meier curves). Although total
leukocyte and monocyte counts were not significant
predictors of event-free survival, high numbers of lympho-
cytes were associated with a decreased risk of cardiovascular
events in dialysis patients. Within monocyte subsets, counts
of CD14þ þCD16þ monocytes significantly predicted and
counts of CD14þ þCD16þ monocytes tended to predict
event-free survival. In contrast, counts of CD14þCD16þ
monocyte had no prognostic impact (Figure 3).
When assessing event-free survival by tertiles of CD14þ þ
CD16þ monocyte counts cross-classified by tertiles of
CRP levels, the percentage of patients suffering cardio-
vascular events and/or death rose across increasing tertiles
of CD14þ þCD16þ monocyte counts for any tertile of
CRP levels. All patients within the third tertile of CRP levels
and the third tertile of CD14þ þCD16þ cell counts suffered
a cardiovascular event or died within the follow-up period
(Figure 4).
Compared with the quartile with the lowest cell counts of
CD14þ þCD16þ monocytes, patients in the top quartile
remained at higher risk of cardiovascular events or death at
35 months when adjusting for age and gender (model 1;
hazard ratio 3.163 (1.341–7.457)), when further adjusting for
diabetes mellitus, smoking, mean blood pressure, plasma
cholesterol, and body mass index (model 2; hazard ratio
4.244 (1.610–11.189)), and when finally further adjusting for
CRP, total leukocyte numbers, prevalent CVD, and vintage of
renal replacement therapy (model 3; hazard ratio 3.702
(1.256–10.916)). The same holds true when stratifying the
patients by relative (percentage of CD14þ þCD16þ cells
among all monocytes) rather than absolute (cells ml1) cell
counts (data not shown).
Healthy control subject
Total monocyte count: 1021 cells/µl
CD14++CD16–
869 cells/µl
CD14++CD16+
56 cells/µl
CD14+CD16+
96 cells/µl
Hemodialysis patient
Total monocyte count: 1116 cells/µl
CD14++CD16–
814 cells/µl
CD14++CD16+
117 cells/µl
CD14+CD16+
185 cells/µl
104
104
103
103
102
102
101
101100
CD16 APC
CD
14
 P
er
CP
104
104
103
103
102
102
101
101100
CD16 APC
CD
14
 P
er
CP
Figure 1 | Monocyte subsets: CD86þ cells with monocyte scatter properties were gated and monocyte subpopulations were defined
according to their surface expression pattern of the LPS receptor CD14 and the Fcc receptor CD16 (representative example of a
hemodialysis patient (74 years of age, male, no prevalent cardiovascular disease at study entry) and an age- and gender-matched
healthy control subject (73 years of age, male, no prevalent cardiovascular disease)).
Table 2 | Univariate correlates of total monocyte counts and counts of monocyte subsets with traditional and non-traditional
cardiovascular risk factors
Total monocytes CD14++CD16 monocytes CD14++CD16+ monocytes CD14+CD16+ monocytes
r P-value r P-value r P-value r P-value
Age (years) 0.224 0.030 0.197 0.057 0.190 0.067 0.108 0.301
Body mass index 0.027 0.799 0.001 0.993 0.003 0.976 0.073 0.487
Mean blood pressure 0.214 0.039 0.163 0.116 0.250 0.015 0.125 0.231
Total cholesterol 0.150 0.149 0.142 0.173 0.219 0.034 0.066 0.528
HDL cholesterol 0.260 0.011 0.201 0.052 0.219 0.034 0.232 0.024
Plasma calcium 0.032 0.760 0.032 0.756 0.038 0.714 0.188 0.069
Plasma phosphorus 0.043 0.681 0.039 0.712 0.019 0.855 0.095 0.360
C-reactive protein 0.167 0.108 0.139 0.181 0.172 0.097 0.018 0.866
HDL, high-density lipoprotein.
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Figure 2 | Survival without cardiovascular events of the cohort by quartiles of total and differential leukocyte counts. Kaplan–Meier
analysis with log-rank test.
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Figure 3 | Survival without cardiovascular events of the cohort by quartiles of differential monocyte counts. Kaplan–Meier analysis with
log-rank test.
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In contrast, neither total monocyte counts nor counts of
CD14þ þCD16 monocytes or CD14þCD16þ monocytes
were independently associated with event-free survival
(Table 3).
DISCUSSION
Atherosclerosis is an inflammatory disease characterized by
the formation of arterial lesions composed of lipids, fibrous
elements, and mononuclear immune cell infiltrates. After
initial injury, endothelial cells secrete proinflammatory mole-
cules that attract circulating monocytes to the nascent lesion.
Monocytes differentiate to macrophages, which perpetuate
the chronic inflammatory process by secreting proinflamma-
tory cytokines and chemokines and thus attracting further
monocytes and T cells.9–11 The central role of monocytes in
the development and progression of atherosclerotic plaques
was experimentally proven by knockout animal studies.25–27
In 1989, heterogeneity among human monocytes was
recognized.28 Subpopulations were defined according to their
surface expression pattern of the lipopolysaccharide receptor
CD14 and the Fcg receptor CD16. Initially, monocytes were
divided into CD16 cells, which were termed ‘classic
monocytes,’ and into CD16þ cells. The latter were supposed
to represent ‘proinflammatory monocytes,’ as they produce
more proinflammatory cytokines (tumor necrosis factor-a)
and less anti-inflammatory cytokines (interleukin (IL)-10)
than CD16 cells, and as their cell count rises in the context
of chronic inflammation, as reviewed recently.29 In 2003, we
reported that patients suffering from chronic artery disease
have more CD16þ monocytes than control subjects,24
suggesting that these seemingly proinflammatory cells might
be involved in atherogenesis.29
Since this initial report, our understanding of monocyte
heterogeneity has grown substantially: firstly, the classifica-
tion of monocyte subpopulations into CD16 and CD16þ
cells has been revised, as recent data suggest that CD16þ
monocytes may be subdivided into functionally distinct
CD14þ þCD16þ and CD14þCD16þ cells.20,30 Secondly,
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Figure 4 | Percentage of patients suffering cardiovascular
events and/or death across tertiles of CD14þ þCD16þ monocyte
counts (Mo 1–3¼ first to third tertiles) and C-reactive protein
(CRP 1–3¼ first to third tertiles). Graded increases in the risk
of cardiovascular events and/or death are found across increasing
tertiles of CD14þ þCD16þ monocyte counts for any tertile of
CRP levels.
Table 3 | Cox regression analysis for cardiovascular events/death
Monocyte subset n
Subjects with
events, n (%) Model 1 P-value Model 2 P-value Model 3 P-value
Total monocytes
1st quartilea 24 9 (37%) 1.0 1.0 1.0
2nd quartile 23 12 (52%) 1.303 (0.547-3.106) 0.551 1.333 (0.545-3.258) 0.529 1.107 (0.421-2.913) 0.837
3rd quartile 24 12 (50%) 1.162 (0.481-2.804) 0.739 1.089 (0.444-2.672) 0.852 0.842 (0.321-2.209) 0.726
4th quartile 23 17 (74%) 2.087 (0.898-4.846) 0.087 1.837 (0.725-4.656) 0.200 1.141 (0.344-3.787) 0.830
CD14++CD16
1st quartilea 23 9 (39%) 1.0 1.0
2nd quartile 24 9 (38%) 0.923 (0.364-2.340) 0.866 0.931 (0.355-2.438) 0.884 0.652 (0.242-1.760) 0.399
3rd quartile 24 15 (63%) 2.084 (0.906-4.794) 0.084 1.950 (0.819-4.642) 0.131 2.126 (0.816-5.540) 0.123
4th quartile 23 17 (74%) 1.775 (0.768-4.102) 0.179 1.603 (0.660-3.894) 0.297 1.528 (0.563-4.147) 0.405
CD14++CD16+
1st quartilea 24 8 (33%) 1.0 1.0 1.0
2nd quartile 23 11 (48%) 1.515 (0.605-3.791) 0.375 1.402 (0.525-3.743) 0.501 0.830 (0.286-2.406) 0.731
3rd quartile 24 15 (62%) 1.905 (0.800-4.532) 0.145 2.023 (0.798-5.125) 0.138 1.825 (0.675-4.939) 0.236
4th quartile 23 16 (70%) 3.163 (1.341-7.457) 0.009 4.244 (1.610-11.189) 0.003 3.702 (1.256-10.916) 0.018
CD14+CD16+
1st quartilea 23 14 (61%) 1.0 1.0 1.0
2nd quartile 24 12 (50%) 0.766 (0.353-1.666) 0.502 0.777 (0.316-1.909) 0.582 0.786 (0.313-1.971) 0.607
3rd quartile 23 11 (48%) 0.556 (0.252-1.227) 0.146 0.603 (0.258-1.409) 0.242 0.455 (0.188-1.098) 0.080
4th quartile 24 13 (54%) 0.791 (0.368-1.701) 0.549 0.856 (0.375-1.954) 0.711 0.465 (0.184-1.176) 0.106
Indicated are hazard ratios, their 95% confidence interval, and the level of significance. Model 1 includes quartile of monocyte (subset) counts, age, and gender; model 2
further adjusted for mean blood pressure, plasma cholesterol, diabetes, smoking, and body mass index; model 3 further adjusted for total leukocyte counts, C-reactive
protein, the prevalence of cardiovascular disease, and vintage of renal replacement therapy.
aPatients in this group served as control group.
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mouse counterparts of human CD14þ þCD16, CD14þ þ
CD16þ and CD14þCD16þ monocyte subsets have been
described, which allows to study the development and the
fate of distinct monocyte subpopulations in vivo.19,20
The distinct subset of CD14þ þCD16þ monocytes is
characterized by their unique pattern of chemokine recep-
tors. They simultaneously express CCR1, CCR2, and
CXCR2—chemokine receptors which are also found on
CD14þ þCD16, but not on CD14þCD16þ cells—and
CX3CR1—a chemokine receptor which is abundantly
expressed on CD14þCD16þ , but not on CD14þ þCD16
monocytes.30 In addition, compared to CD14þ þCD16 and
CD14þCD16þ monocytes, CCR5 expression is increased
on CD14þ þCD16þ monocytes.30 The importance of CCR5
in atherogenesis has been illustrated by two recent animal
studies, in which genetic deletion of CCR5 protected ApoE/
mice from diet-induced atherosclerosis31 and from neointima
formation after arterial injury.32 In both models, lesional
macrophage accumulation was reduced in CCR5/ knockout
mice.31,32
Thus, CD14þ þCD16þ monocytes may possess a wider
range of chemokine pathways for recruitment into athero-
sclerotic lesions than CD14þ þCD16 or CD14þCD16þ
monocytes, comprising the higher expression of CCR5. In
addition, we recently reported a subset-specific upregulation
of membrane-bound angiotensin-converting enzyme (ACE;
CD143) on CD14þ þCD16þ monocytes, which might
enhance oxidative stress and endothelial dysfunction at the
site of vascular lesions.33
The identification of monocyte heterogeneity in mice
allowed a deeper understanding of the physiological role of
monocyte subsets in vivo, as reviewed recently.19,20 Bone
marrow-derived monocytes that enter the circulation are
characterized as Ly6CþCX3CR1þ cells, which are counter-
parts of human CD14þ þCD16 monocytes. After 5 days,
these cells begin to convert to the transient population of
Ly6CmidCX3CR1þ monocytes, equivalents of human
CD14þ þCD16þ monocytes, and finally to Ly6CCX3CR1þ þ
monocytes, which are counterparts of CD14þCD16þ mono-
cytes.20 Both Ly6CþCX3CR1þ and Ly6CmidCX3CR1þ
monocytes may migrate into inflammatory lesions, in which
the former differentiate into macrophages, whereas the
latter may alternatively become dendritic cells.34 In contrast,
Ly6CCX3CR1þ þ monocytes have been suggested to invade
inflammatory lesions only sparsely, and rather to replace
resident macrophages or dendritic cells in non-inflamed
tissues.20 This concept has been challenged by a recent report
that found that Ly6CCX3CR1þ þ monocytes may migrate
into inflamed lungs, where they may develop into both
macrophages and dendritic cells.35 It is thus increasingly
acknowledged that migration and differentiation patterns of
monocyte subsets may differ in different tissues.36
Tacke and co-workers34 were recently able to directly prove
a subset-specific migration of monocytes in atherosclerosis: the
counterparts of CD14þ þCD16 cells (Ly6CþCX3CR1þ
cells) may invade atherosclerotic lesions via their CCR2 and
CX3CR1 chemokine receptors, whereas the counterparts
of CD16þ monocytes (Ly6CCX3CR1þ þ cells) are partly
dependent on CCR5 to invade plaques. As in humans, CCR5
is strongly expressed on CD14þ þCD16þ monocytes, it may
be speculated that among CD16þ monocytes, CD14þ þ
CD16þ rather than CD14þCD16þ monocytes are prone to
invade atherosclerotic plaques, even though this hypothesis
awaits experimental confirmation.
Our findings supplement these animal data by demons-
trating for the first time that distinct monocyte subsets are
associated with event-free survival in a specific cohort of
cardiovascular high-risk patients. Among dialysis patients,
counts of CD14þ þCD16þ monocytes are independently
associated with event-free survival, whereas counts of
CD14þ þCD16 monocytes tend to predict event-free
survival in univariate, but not in multivariate analysis, and
CD14þCD16þ monocytes are not predictors of event-free
survival at all.
Dialysis patients were found to have higher counts of
CD14þ þCD16þ and CD14þCD16þ monocytes compared
to controls with intact renal function. Earlier studies from
our23 and other groups (reviewed by Ziegler-Heitbrock29)
ignored heterogeneity within CD16þ monocytes when
reporting increased CD16þ monocyte counts in dialysis
patients. We suggest that high CD14þ þCD16þ monocyte
counts may contribute to the accelerated atherogenesis in
dialysis patients.
Epidemiological studies can never prove causality, but
only detect associations. We cannot prove that high
CD14þ þCD16þ monocyte counts cause initiation and
progression of atherosclerotic lesions, and we cannot exclude
that changes in CD14þ þCD16þ monocyte subset counts
might reflect a downstream event from an atherosclerotic
lesion.
In addition, the study is limited by the relatively small
number of patients included.
Pathophysiological pathways in atherogenesis differ bet-
ween patients with intact and impaired renal function, and
cell counts of CD14þ þCD16þ monocytes are significantly
lower in individuals without chronic kidney disease. There-
fore, our results cannot be transferred from dialysis patients
to the general population. Even though we earlier reported
increased counts of CD16þ monocytes in patients suffering
from coronary heart disease compared to healthy controls,24
this study did not distinguish between CD14þ þCD16þ and
CD14þCD16þ monocytes, and it did not provide outcome
data.
We are currently initiating an epidemiological study
on the prognostic impact of monocyte subpopulations
in individuals with intact renal function. Until results from
this study are available, CD14þ þCD16þ monocyte counts
should not be considered prognostic markers in other
populations than dialysis patients.
Variability in measurement of monocyte counts might
have affected our results. Monocyte subpopulation counts,
however, remained remarkably stable over a time period of
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4 months, with strong correlations between replicate cell
counting (Spearman’s coefficients of 0.672–0.746).
In conclusion, CD14þ þCD16þ monocyte counts rather
than total monocyte counts predict event-free survival in
dialysis patients. This finding is in agreement with recent
animal studies, which suggest a selective role of distinct
monocyte subsets in atherosclerosis.
MATERIALS AND METHODS
Study population
In March 2004, 94 patients with prevalent end-stage renal disease
who underwent hemodialysis treatment (n¼ 75) or PD treatment
(n¼ 19) were included in a prospective cohort study. End-stage
renal disease was due to diabetic nephropathy (n¼ 27), glomerulo-
nephritis (n¼ 24), nephrosclerosis (n¼ 10), polycystic kidney
disease (n¼ 6), interstitial nephritis (n¼ 4), reflux nephropathy
(n¼ 4), or other primary renal diseases (n¼ 12). Primary renal
disease was unknown in seven patients. Patients had a mean vintage
of renal replacement therapy of 3.7±4.5 years. Hemodialysis was
performed using bicarbonate dialysate and polyamide or poly-
sulfone dialysers. PD was performed using standard PD solutions
(Physioneal/Dianeal; Baxter, Unterschleißheim, Germany, or Stay
Safe/Balance; Fresenius, Bad Homburg, Germany). All patients were
of Caucasian ethnicity with the exception of one patient who was of
Asian ethnicity. Patients with any medical complication necessitat-
ing hospitalization at study initiation were excluded.
Systolic and diastolic blood pressure (BP sys and BP dia) was
measured before a dialysis session in HDs or during an outpatient
clinic appointment in PD patients. Mean blood pressure was defined
as BP diaþ (BP sysBP dia)/3.
Patients with a history of diabetes mellitus, with a spontaneous
plasma glucose level of 4200 mg per 100 ml and/or anti-diabetic
treatment, and patients with self-reported diabetes mellitus were
categorized as diabetic. Patients were categorized as active smokers if
they were current smokers or had stopped smoking o1 month
before entry into the study. Body mass index was calculated as body
weight (kg)/height (m)2.
Comorbidity was assessed by chart review and by standardized
interviews of all patients and controls. Prevalent CVD was diagnosed
in patients with coronary artery disease (a history of myocardial
infarction or coronary artery angioplasty/stenting/bypass surgery),
cerebrovascular disease (a history of major stroke or carotid
endarterectomy/stenting), or peripheral artery disease (a history of
non-traumatic lower extremity amputation or lower limb artery
bypass surgery/angioplasty/stenting).
Twenty-seven age-matched controls were recruited from the
Department of Ophthalmology, University of Saarland, to compare
monocyte (subset) counts between dialysis patients and individuals
without chronic kidney disease.
Informed consent was obtained from all patients and controls,
and the study design was approved by the local ethics committee.
Laboratory methods
Blood was drawn before the start of the mid-week hemodialysis
session in HDs and during an outpatient clinic appointment in PD
patients. Plasma glucose, total cholesterol, high-density lipoprotein
cholesterol, calcium, phosphorus, albumin, and CRP were obtained
using standard techniques.
Leukocyte and monocyte counts were measured with automated
cell counters by standard techniques. Monocyte subpopulations
were flow cytometrically analyzed in a whole blood assay using
100 ml of heparin anticoagulated blood, as described before.33 In
brief, cells were stained by monoclonal antibodies (as listed below)
and analyzed by flow cytometry (FACSCalibur; BD Biosciences,
Heidelberg, Germany) using the Cell Quest software.
Monocytes were gated in an SSC/CD86þ dotplot, identifying
monocytes as CD86þ cells with monocyte scatter properties.
Subsets of CD14þ þCD16, CD14þ þCD16þ , and CD14þCD16þ
monocytes were defined according to the surface expression pattern
of the lipopolysaccharide receptor CD14 and the Fcg receptor CD16
(compare Figure 1 for a representative example). The following
antibodies were used: CD86 (HA5.2B7; Beckman-Coulter, Krefeld,
Germany), CD16 (3G8; Caltag, Hamburg, Germany), CD14 (Mf9,
BD Biosciences).
In 60 patients, monocytes were measured twice to assess the
stability of cell counts over time, with a time interval of 4 months
between both measurements. These 60 patients did not differ from
the remaining patients in age, total leukocyte and total monocyte
counts, CD14þ þCD16þ monocyte counts, prevalence of diabetes
mellitus, and prevalence of CVD.
The Spearman correlations between the readings at baseline and
at re-analysis were 0.746 (CD14þ þCD16 cells; Po0.001), 0.672
(CD14þ þCD16þ cells; Po0.001), and 0.678 (CD14þCD16þ cells;
Po0.001).
All participants were followed from the baseline examination
until death or until 31 December 2006. Patients who received a
renal allograft were censored at the time of kidney transplantation.
No patient was lost to follow-up. The prespecified clinical end
points were death and cardiovascular events, defined as myocardial
infarction, coronary artery angioplasty/stenting/bypass surgery,
major stroke, carotid endarterectomy/stenting, nontraumatic lower
extremity amputation, or lower limb artery bypass surgery/
angioplasty/stenting.
Statistical analysis
Categorical variables are presented as percentage of patients and
compared by Fisher’s exact test.
Continuous data are expressed as means±s.d. and compared
by the Mann–Whitney test. For measuring the relationship
between monocyte (subset) counts and cardiovascular risk factors,
Spearman’s correlation coefficients were calculated.
Subjects were divided into four equally sized groups (quartiles)
according to their total or differential leukocyte/monocyte counts.
Kaplan–Meier survival curves were used to compare event-free
survival by quartiles of total and differential leukocyte/monocyte
counts at baseline. The log-rank test was used to test the hypothesis
that at least one of the survival curves differs from the others.
To understand the relative predictive value of CD14þ þCD16þ
monocyte counts vs CRP levels, we assessed the percentage
of patients suffering cardiovascular events and/or death by tertiles
of CD14þ þCD16þ monocyte counts cross-classified by tertiles of
CRP levels; tertiles were used instead of quartiles to avoid small
numbers in individual cells.
Cox proportional hazards models were calculated to study
relationships of baseline total and differential monocyte counts
with event-free survival, adjusting for age and gender (model 1),
age, gender, and other classical cardiovascular risk factors (model 2:
body mass index, mean blood pressure, smoking, diabetes mellitus,
plasma cholesterol), and all these classical cardiovascular risk
factors, total leukocyte counts, CRP, prevalence of CVD at baseline,
and vintage of renal replacement therapy (model 3).
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Data management and statistical analysis were performed with
SPSS 12.0.1. The level of significance was set at Pp0.05. As P values
are not adjusted for multiple testing, they have to be considered as
descriptive.
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